<DOC>
	<DOC>NCT02631694</DOC>
	<brief_summary>Animal and human fear conditioning studies have repeatedly shown that administering propranolol before or after retrieval of a previously acquired fear results in an elimination of the fear expression. This approach, known as disruption of fear memory reconsolidation, is a promising new avenue for treating anxiety disorders. The present study aims to test its efficacy in patients with panic disorder.</brief_summary>
	<brief_title>Disruption of Memory Reconsolidating as a Treatment for Panic Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Panic Disorder</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<criteria>a primary diagnosis of panic disorder according to DSMV written approval of an independent physician for participation other relevant treatment for panic disorder at the time of study e.g., Cognitive Behavioral Therapy (CBT) diagnosis of depression diagnosis of psychosis use of psychotropic medication history of pulmonary diseases metabolic acidosis history of cardiovascular diseases heart problems among firstdegree relatives heart rate (HR) &lt; 60 blood pressure (BP) &lt; 9060 or BP &gt; 170100 history of blackouts or fainting diabetes liver or kidney diseases hyperactive production of thyroid hormones epilepsy any medication contraindicative of the use of propranolol pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>